Marcus Moeller

Professor Moeller has received a broad scientific training in various institutions, until he established a research group at the RWTH Aachen University, Germany, in 2004. During this time, he created the transgenic technology that is now used worldwide to target podocytes or glomerular parietal epithelial cells (PECs) in vivo. Scientifically, he has established two major areas of interest: mechanisms in glomerular pathology (in particular FSGS and crescentic glomerulonephritis) and glomerular filtration and the pathogenesis of proteinuria.